Uses
To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.
Source: US FDA prescribing information
Molecule
Prochlorperazine
Also known as prochlorperazine edisylate, prochlorperazine maleate
Available on requestPsychiatry
- Presentations
- 6
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Prochlorperazine is a phenothiazine. It is available as tablets, injection and suppositories for oral, intramuscular and intravenous use. MedsAcross supplies Prochlorperazine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Phenothiazine
- ATC classification
- N05AB04 Prochlorperazine · Antipsychotics, subgroup N05AB
- US FDA first approval
- 23 October 1956
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Oral, Intramuscular, Intravenous, Rectal
- Dosage forms
- Tablet, Injection, Suppository
- Identifiers
- UNII YHP6YLT61TRxCUI 8704CAS 58-38-8DrugBank DB00433Q2359690
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
NOTE ON INJECTION: For intramuscular administration, inject deeply into the upper, outer quadrant of the buttock. Subcutaneous administration is not advisable because of local irritation. Stability This solution should be protected from light. Slight yellowish discoloration will not alter potency. If markedly discolored, solution should be discarded. Compatibility It is recommended that Prochlorperazine Edisylate Injection not be mixed with other agents in the syringe. Adults (For children’s dosage and administration, see below.) Dosage should be increased more gradually in debilitated or emaciated patients. ELDERLY PATIENTS In general, dosages in the lower range are sufficient for most elderly patients. Since they appear to be more susceptible to hypotension and neuromuscular reactions, such patients should be observed closely.
Source: US FDA prescribing information
Contraindications
Do not use in patients with known hypersensitivity to phenothiazines. Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). Do not use in pediatric surgery. Do not use in pediatric patients under 2 years of age or under 20 lbs. Do not use in children for conditions for which dosage has not been established.
Source: US FDA prescribing information
Warnings and precautions
WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Prochlorperazine Edisylate Injection, USP is not approved for the treatment of patients with dementia-related psychosis.
Source: US FDA prescribing information
Side effects
Drowsiness, dizziness, amenorrhea, blurred vision, skin reactions and hypotension may occur. Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. Cholestatic jaundice has occurred. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment. There have been a few observations of fatty changes in the livers of patients who have died while receiving the drug. No causal relationship has been established. Leukopenia and agranulocytosis have occurred. Warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate leukocyte depression, stop treatment and start antibiotic and other suitable therapy.
Source: US FDA prescribing information
Storage
Store in the box until ready to use. Store at 20 º -25 º C (68 º -77 º F), excursions permitted to 15 º -30 º C (59 º -86 º F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
6 presentations of Prochlorperazine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Prochlorperazine 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Prochlorperazine 5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Prochlorperazine 10 mg/2 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
| Compro 25 mg suppositoryRectal | Padagis | US FDA | Available on request |
| Prochlorperazine 25 mg suppositoryRectalGeneric name | — | US FDA | Available on request |
| Prochlorperazine 50 mg/10 mL injectionIntramuscular, intravenousGeneric name | — | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 23 October 1956 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Prochlorperazine in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Prochlorperazine available for export from India?
Yes, on request. MedsAcross lists 6 presentations of Prochlorperazine and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Prochlorperazine have?
The catalogue lists 1 brand names for Prochlorperazine, including Compro.
Is Prochlorperazine approved by the US FDA?
Yes. The US FDA first approved Prochlorperazine on 23 October 1956, according to Drugs@FDA.
Does Prochlorperazine need cold chain shipping?
No listed presentation of Prochlorperazine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Prochlorperazine in?
Prochlorperazine is classified under ATC code N05AB04 (Prochlorperazine).
References
- Prochlorperazine Edisylate prescribing information (Civica). U.S. National Library of Medicine, DailyMed. Retrieved 23 October 2026
Request Prochlorperazine for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.